Internet Pioneer In...
Health Care: Drugs
Durect Corporation (DRRX: NASDAQ)
$0.82 -0.01 | -1.10%
06/04/12 - 09:38 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 3.90 | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 18.60 | 12.50 |
| Beta | 1.15 | 0.62 | 0.98 |
| Price to Sales (TTM) | 1.10 | 4.29 | 1.42 |
| Price to Book (MRQ) | 2.02 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 2.46 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | 3.70 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.60 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 378.70 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 6.00 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 8.62 | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -19.57 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 4.80 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 5.70 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.37 | 0.96 |
| Interest Coverage (TTM) | 376.90 | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 94.40 | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 93.20 | 75.30 | 47.70 |
| EBITD Margin (TTM) | 29.40 | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | -110.76 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 27.90 | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -95.30 | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.28 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -95.30 | 8.60 | 7.00 |
| Return on Assets (TTM) | 42.20 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | -42.00 | 4.60 | 2.50 |
| Return on Investment (TTM) | 51.20 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -117.00 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 623,283.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | 173,783.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | 19.60 | 4.70 | 7.60 |
| Inventory Turnover (TTM) | 1.20 | 1.70 | 8.30 |
| Asset Turnover (TTM) | 1.30 | 0.60 | 0.40 |
Portfolios with DRRX
- Portfolio NameUser Type
- ProRobert Bruce
- Userdonellisor
- UserTrading
- Userbaustin002 Portfolio 1
- UserBarron's Research Reports 1...
- Userhititbig
- Userbv2
- UserFBSPANKEY Portfolio 1
- Usersandw1ch Portfolio 1
- Usermiguele4 Portfolio 1
Latest DRRX Headlines from TheStreet
- Business Highlights 06.24.11 | 06:06 pm
- Durect Stock Gaps Down On Today's Open (DRRX) 06.24.11 | 09:06 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
- 10 Stocks to Watch: Alcoa, BP 04.12.11 | 06:04 am
- Biotech Calendar: 2011 FDA Drug Approvals 02.22.11 | 07:02 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences 09.07.10 | 06:09 pm
- DURECT Corporation Q1 2010 Earnings Call Transcript 05.11.10 | 01:05 am
- Durect Says Pain Patch Met Goals In Clinical Study 03.16.09 | 02:03 pm
- Thursday's Winners & Losers: Durect 05.08.08 | 04:05 pm
- Health Winners & Losers: Barr 05.08.08 | 04:05 pm
Press Releases for DRRX
- DURECT Receives Back U.S. And Canadian Product Rights To POSIDUR⢠- PR Newswire 03.29.12 | 04:03 pm
- DURECT Corporation Invites You To Join Its Fourth Quarter 2011 Earnings Conference Call - PR Newswire 02.24.12 | 09:02 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 02.23.12 | 11:02 am
- DURECT To Present At The BIO CEO & Investor Conference - PR Newswire 02.07.12 | 12:02 pm
- DURECT Receives Back European Product Rights To POSIDUR⢠- PR Newswire 01.30.12 | 04:01 pm
- DURECT Announces Top-line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial) - PR Newswire 01.05.12 | 04:01 pm
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 11.07.11 | 08:11 am
- DURECT Corporation Invites You To Join Its Third Quarter 2011 Earnings Conference Call - PR Newswire 10.26.11 | 05:10 pm
- DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST) - PR Newswire 09.06.11 | 07:09 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 08.31.11 | 04:08 pm
Partner Headlines for DRRX
- Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT - Benzinga 03.01.12 | 04:03 pm
- DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance - Benzinga 01.05.12 | 04:01 pm
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX) - Benzinga 08.05.10 | 09:08 am
- FDA Clears Hospira's Generic Drug - Analyst Blog - Zacks 06.25.10 | 01:06 pm
- UPDATE 1-Durect's pain drug shows mixed results in EU trial - Reuters 06.16.10 | 05:06 pm
- King Advances Pain Candidate - Analyst Blog - Zacks 04.08.10 | 06:04 pm
